Literature DB >> 1312485

Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin.

N Bucurenci1, D R Blake, K Chidwick, P G Winyard.   

Abstract

We report here that human plasma alpha 1-antitrypsin (alpha 1-AT) inhibited human neutrophil O2.- release elicited by a variety of stimulants. In comparison, the inhibitory capacities of two serine protease inhibitors, L-1-tosylamide 2-phenylethyl chloromethyl ketone (TPCK) and soybean trypsin inhibitor (SBTI), and the human recombinant alpha 1-AT mutant, alpha 1-AT-Arg358 were in the order: alpha 1-AT = TPCK much greater than alpha 1-AT-Arg358 greater than SBTI when cells were stimulated with concanavalin A plus cytochalasin E. These data suggest that, in human inflammatory fluids containing relatively high concentrations of alpha 1-AT (such as rheumatoid arthritis synovial fluid), (i) alpha 1-AT may down-regulate the inflammatory process by inhibiting the neutrophil respiratory burst and (ii) serpin oxidation by neutrophil-released reactive oxygen species is unlikely to occur.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312485     DOI: 10.1016/0014-5793(92)80156-b

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

1.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

2.  Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.

Authors:  Mariam Al-Omari; Elena Korenbaum; Matthias Ballmaier; Ulrich Lehmann; Danny Jonigk; Dietmar J Manstein; Tobias Welte; Ravi Mahadeva; Sabina Janciauskiene
Journal:  Mol Med       Date:  2011-04-11       Impact factor: 6.354

Review 3.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

Review 4.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

Review 5.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

6.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

7.  Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and generation of reactive oxygen species.

Authors:  S Y Lim; G M Tennant; S Kennedy; C L Wainwright; K A Kane
Journal:  Br J Pharmacol       Date:  2006-09-18       Impact factor: 8.739

8.  An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana.

Authors:  David Z Silberstein; Kalimuthu Karuppanan; Hnin Hnin Aung; Ching-Hsien Chen; Carroll E Cross; Karen A McDonald
Journal:  Free Radic Biol Med       Date:  2018-03-16       Impact factor: 7.376

9.  Serine protease inhibitors inhibit superoxide release and adherence in human neutrophils stimulated by granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha.

Authors:  Yue-Min Zhou; Haruo Kutsuna; Kenichi Suzuki; Fumihiko Hato; Seiichi Kitagawa
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

10.  α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide induced IL-1β in human blood neutrophils.

Authors:  Nupur Aggarwal; Elena Korenbaum; Ravi Mahadeva; Stephan Immenschuh; Veronika Grau; Charles A Dinarello; Tobias Welte; Sabina Janciauskiene
Journal:  Mol Med       Date:  2016-10-04       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.